Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
Authors:
- William R. LumryWLWilliam R. Lumry
- Karsten WellerKWKarsten Weller
- Marc A. RiedlMRMarc A. Riedl
- Marcus MaurerMMMarcus Maurer
- the HELP Study InvestigatorsTIthe HELP Study Investigators
Open Access
- 30 November 2020
- Vol. 76 (4) , 1188-1198
Abstract
Background: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE).Methods: Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or placebo (n = 41) for 26 weeks (days 0–182). The Angioedema Quality of Life Questionnaire (AE‐QoL) was administered monthly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. The generic EQ‐5D‐5L questionnaire was administered on days 0, 98, and 182. Comparisons were made between placebo and (a) all lanadelumab‐treated patients and (b) individual lanadelumab groups for changes in scores (day 0–182) and proportions achieving the minimal clinically important difference (MCID, −6) in AE‐QoL total score.Results: Compared with the placebo group, the lanadelumab total group demonstrated significantly greater improvements in AE‐QoL total and domain scores (mean change, −13.0 to −29.3; p < 0.05 for all); the largest improvement was in functioning. A significantly greater proportion of the lanadelumab total group achieved the MCID (70% vs 37%; p = 0.001). The lanadelumab 300 mg q2wks group had the highest proportion (81%; p = 0.001) and was 7.2 times more likely to achieve the MCID than the placebo group. Mean EQ‐5D‐5L scores at day 0 were high in all groups, indicating low impairment, with no significant changes at day 182.Conclusion: Patients with HAE‐1/2 experienced significant and clinically meaningful improvements in HRQoL measured by AE‐QoL following lanadelumab treatment in the HELP Study.Keywords
This publication has 41 references indexed in Scilit:
- The burden of illness in patients with hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2013
- Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patientsAnnals of Allergy, Asthma & Immunology, 2013
- Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous UrticariaDermatology, 2013
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research projectHealth and Quality of Life Outcomes, 2012
- Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving TreatmentArchives of Dermatology, 2011
- The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depressionAllergy and Asthma Proceedings, 2010
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- Local bradykinin generation in hereditary angioedema☆☆☆★Journal of Allergy and Clinical Immunology, 1999